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Abstract
The mouse polyoma virus induces a broad array of solid tumors in mice of many inbred strains. In most strains tumors grow
rapidly but fail to metastasize. An exception has been found in the Czech-II/Ei mouse in which bone tumors metastasize regularly
to the lung. These tumors resemble human osteosarcoma in their propensity for pulmonary metastasis. Cell lines established
from these metastatic tumors have been compared with ones from non-metastatic osteosarcomas arising in C3H/BiDa mice.
Osteopontin, a chemokine implicated in migration and metastasis, is known to be transcriptionally induced by the viral middle T
antigen. Czech-II/Ei and C3H/BiDa tumor cells expressed middle T and secreted osteopontin at comparable levels as the major
chemoattractant. The tumor cell lines migrated equally well in response to recombinant osteopontin as the sole attractant. An
important difference emerged in assays for invasion in which tumor cells from Czech-II/Ei mice were able to invade across an
extracellular matrix barrier while those from C3H/BiDa mice were unable to invade. Invasive behavior was linked to elevated
levelsofthemetalloproteinaseMMP-2andofthetranscriptionfactorNFAT.InhibitionofeitherMMP-2orNFATinhibitedinvasion
by Czech-II/Ei osteosarcoma cells. The metastatic phenotype is dominant in F1 mice. Osteosarcoma cell lines from F1 mice
expressed intermediate levels of MMP-2 and NFAT and were invasive. Osteosarcomas in Czech-II/Ei mice retain functional p53.
This virus-host model of metastasis differs from engineered models targeting p53 or pRb and provides a system for investigating
the genetic and molecular basis of bone tumor metastasis in the absence of p53 loss.
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Introduction
Invasion and metastasis are major factors underlying cancer
morbidity and mortality [1]. Mouse models have been developed
for many types of human cancer though not all present the same
biological behavior as human tumors with respect to invasion and
metastasis. Some models are of spontaneous origin while most are
based on genetically engineered animals. Transgenic mice, mice
with germline or conditional knockouts, targeted mutations [2], or
ones emerging from screens following germline mutagenesis [3]
have all been used to establish experimental models of specific
types of cancer. Mice genetically engineered to develop cancer are
typically derived from relatively few inbred strains thus reflecting a
limited range of effects imposed by the host genetic background.
Crosses of genetically engineered mice to other strains have been
useful for identifying tumor modifiers [4,5].
The mouse polyoma virus (Py) is a small DNA virus that rapidly
induces a variety of solid tumors in its natural host under
laboratory conditions [6]. The virus establishes a disseminated
infection using specific gangliosides as broadly expressed cell
receptors [7]. Features of the major viral capsid protein VP1 are
important in receptor discrimination and polymorphisms in VP1
are major determinants of pathogenicity [8,9]. The replication and
transforming functions of the virus reside in the T (tumor)
antigens. These have been extensively characterized using cell
culture systems. Expression of the T antigens leads to alterations in
the regulation of growth and apoptotic pathways of the cell. These
alterations involve both protooncogene activation and tumor
suppressor gene inactivation. Well characterized wild type and
mutant virus strains have been used to assess the roles of specific
viral determinants in tumorigenesis using a standard inbred mouse
strain as the common host [10–13].
The virus can be introduced into any of a large number of
inbred strains of mice to investigate effects of the host genetic
background on various aspects of tumor development. Inbred
mice vary greatly with respect to overall tumor frequency,
spectrum of tumor types, and individual tumor behavior [6]. Py-
induced tumors typically remain at the site of origin enclosed
within a basement membrane. Susceptible hosts develop multiple
tumors and may carry a cumulative tumor load in excess of 25%
of total body weight while showing no evidence of metastasis [14].
The middle T antigen, the major viral transforming protein,
activates multiple signal transduction pathways essential for tumor
induction [15]. Transgenic mice expressing middle T under
control of the mouse mammary tumor virus regulatory region
develop mammary tumors which metastasize to the lung [16]. In
this transgenic mouse system, secretion of osteopontin (OPN) was
found to be necessary but not sufficient for metastasis [17].
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Py [6], the Czech II/Ei mouse (CZ) emerged with unique and
interesting properties. In addition to a typical array of polyoma
tumors [18], CZ mice occasionally developed small nodules on the
lung, normally not a site of tumor induction by the virus. These
nodules proved to be metastatic lesions derived from osteosarco-
mas. The metastatic behavior of bone tumors in the Py-infected
CZ mouse matches important clinical and pathological features of
human osteosarcoma with respect to lung metastases [19]. C3H/
BiDa mice (C3), a standard susceptible strain [20], develop
osteosarcomas that fail to metastasize. Here we begin to explore
the CZ mouse as a model of metastatic osteosarcoma using the C3
mouse as a control. A molecular pathway has been identified that
correlates with properties of invasion in vitro and metastasis in vivo.
Results/Discussion
Bone tumor metastasis to the lung is determined by the
host genetic background
Osteosarcomas have previously beennoted in Py-infected miceof
several inbred strains but with no evidence of metastasis. In CZ
mice, however, these tumors have been found to metastasize
regularlytothe lung.Osteosarcomasdevelop most frequentlyonthe
femur, skull, ribs or other long bones, and occasionally on the spine
and sternum. A typical case in a CZ mouse is shown in Figure 1.
The primary tumor arose on the head of the femur (panel A). This
Author Summary
The oncogenic mouse polyoma virus and its mutants have
previously been used to investigate viral determinants of
tumor induction using a standard inbred mouse strain as a
common host. Here we use wild type virus to investigate
the role of the host genetic background, focusing on two
host strains that differ with respect to bone tumor
metastasis. Comparing osteosarcoma cell lines from these
mice, we have identified a molecular pathway that
underlies invasive behavior in vitro and correlates with
metastasis in vivo. The pathway involves secretion of the
metalloproteinase MMP-2 under partial control of NFAT as
a transcriptional regulator. This virus-host system reflects
an important feature of human osteosarcoma with respect
to pulmonary metastasis. Based on naturally occurring
differences among inbred mice, the model differs from
genetically engineered models targeting p53 or pRb as
known risk factors in the human disease. Here, metastatic
osteosarcomas retain functional p53. As noted by others,
the frequency of p53 loss in patients with localized versus
metastatic disease is the same, suggesting that events
beyond p53 loss are important in metastasis. While the
downstream effectors of metastasis in the genetically
engineered models remain unknown, evidence presented
here implicates upregulation of an NFAT R MMP-2
pathway in the development of metastatic osteosarcoma.
Figure 1. Primary and metastatic bone tumors from CZ mice. A) A primary bone tumor (P) on the head of the femur of a CZ mouse. B) H&E
stained section of the same tumor showing invasion of adjacent muscle and destruction of bone by invading tumor cells. C) Metastatic nodule (Mx)
on the surface of the lung of the same animal. D) H&E stained section of the lung metastasis from the same animal showing osteiod. E) Occult
metastatic lesion with osteoid in the lung of a different CZ animal. F) H&E stained section of a liver metastasis showing osteoid in a CZ animal
inoculated with osteosarcoma cells.
doi:10.1371/journal.ppat.1000733.g001
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destruction of bone (panel B). A metastatic lesion was evident as a
smooth shiny nodule on the surface of the lung (panel C). This
nodule showed abundant tumor cells mixed with deposits of osteoid
(panel D). Lung metastases were seen in a high percentage of CZ
mice by routine step-sectioning and histological examination. These
lesions consistently showed production of osteoid (panel E).
Metastases were noted rarely in the liver. To confirm that the liver
lesions in Py-infected CZ mice also derived from osteosarcomas,
cells from a primary bone tumor were inoculated subcutaneously
into an uninfected CZ mouse. This animal showed growth of tumor
cells in the liver with deposits of osteoid (panel F). The presence of
osteoid in metastastic lesions in CZ mice confirms their origins from
osteosarcomas and not from other tumor types arising in the same
animals. Further support derives from the fact that no lung
metastases were noted in CZ mice that failed to develop primary
osteosarcoma while developing other kinds of tumors.
Osteosarcomas in C3 mice resembled those in CZ mice
grossly and histologically. However, these tumors showed no
evidence of lung metastasis using the same search criteria as for
CZ mice. A direct comparison of the frequencies of primary and
metastatic osteosarcoma in CZ and C3 mice highlights
important differences between these strains (Table 1). A high
proportion of CZ mice developed osteosarcomas and 90% of
these were found to have metastasized to the lung. The actual
frequency of lung metastasis in CZ mice may approach 100%
given the likelihood that not all lesions will be found in the step
sectioning process. Osteosarcomas in C3 mice were found at a
lower frequency due in part to higher frequencies of other tumor
types that develop early and require the animals to be sacrificed.
Nevertheless, of 18 cases of osteosarcoma in C3 mice, none were
found to have metastasized to the lung. The sharp difference in
f r e q u e n c yo fm e t a s t a s i sb e t w e e nh o s t si sn o td u et od i f f e r e n c e si n
t h et i m ea l l o w e df o rt u m o rd e v e l o p m e n t .T h ea v e r a g e‘ t i m et o
necropsy’ was 190 days for CZ and 188 for C3, with ranges of
104–514 days for CZ and 70 – 655 for C3.
[CZ x C3] F1 mice were infected and followed for the
development of osteosarcoma and then screened for lung metastases.
These mice were found to resemble their CZ parent with respect to
the high frequency and metastatic behavior of osteosarcomas
(Table 1). The dominance of the metastatic phenotype suggests that
CZ mice express a heritable factor(s) which promotes bone tumor
metastasis and which may be lacking or insufficient in C3 mice.
CZ and C3 bone tumor cells secrete and migrate equally
well in response to osteopontin
To investigate the molecular basis of the metastatic phenotype, cell
lines were established from primary osteosarcomas, two from CZ,
three from C3 and two from F1 mice. Two additional lines were
derived from lung metastatic lesions, one from a CZ and one from an
F1 animal. It should be noted that no osteosarcomas were found in
uninfected mice of either strain and expression of the Py T antigens
was confirmed in each of the cell lines from infected mice (data not
shown). The abilities of the tumor cells to migrate in response to a
source of chemoattractant were tested in a transwell assay using a
Boyden chamber with polycarbonate filter (8 mm pore size).
Conditioned medium from a C3 osteosarcoma line was used as the
attractant and serum-free medium as a control. Migration was
stimulated 3–4 fold over a one hour period in response to the
conditioned medium. No significant differences were noted among
the lines (Figure 2A).
To identify the chemoattractant(s), the conditioned medium was
first treated with antibodies to OPN or to vascular endothelial growth
factor (VEGF). These factors, well recognized for their chemoat-
tractant as well as mitogenic activities, play roles in normal bone
development as well as tumor cell invasion and metastasis. OPN is of
particular interest because expression of middle T has been shown to
lead to transcriptional activation of OPN via two distinct pathways
[21]. Furthermore, in an in vitro ‘wound healing’ assay, blocking
induction of OPN with anti-sense RNA inhibited cell migration
without interfering with transformed cell growth [21]. Pretreatment
of conditioned medium with anti-OPN resulted in significant
reduction in the migration of CZ-I cells while anti-VEGF had no
effect (Figure 2B, left panel). Results were the same using the other
lines as responding cells (data not shown). To determine whether the
pathways from middle T to OPN operated equally in the two host
backgrounds, levels of OPN were compared in conditioned media
prepared from CZ and C3 bone tumor lines. Levels were found to be
high and comparable between the two groups: 19756262 pg/ml for
the two CZ lines and 1592638 pg/ml for the three C3 lines.
Similarly, levels of VEGF, though much lower, were comparable:
153612 pg/ml for CZ and 225613 pg/ml for C3.
Additional experiments were carried out to test the specificity of
migration in relation to these factors and also with respect to tumor
type. Conditioned medium from a Py-induced hemangioma in a C3
mouse contained a higher level of VEGF (792638 pg/ml) and a
similar level of OPN (1622620 pg/ml) compared to osteosarcoma
conditioned media. Migration of CZ cells was again inhibited only by
anti-OPN and not by anti-VEGF (Figure 2B, middle panel). In
contrast, migration of the hemangioma cells in response to its own
conditioned medium was inhibited by anti-VEGF as well as anti-OPN
(Figure 2B, right panel). These results confirm OPN as the major
attractant for osteosarcoma cells. They also demonstrate specificity in
migratory behavior based on tumor type as well as attractant.
The osteosarcoma lines were compared for their abilities to
migrate in response to recombinant OPN added to serum-free
medium as the sole attractant. All nine lines responded well with
no significant differences among the lines (Figure 2C). We
conclude that the difference in metastatic behavior between CZ
and C3 osteosarcomas is not due to a difference either in
production of OPN or in ability to migrate in response to this
factor. This conclusion is consistent with studies of mammary
tumor metastasis in Py middle T transgenic mice which indicated
that factor(s) in addition to OPN are required for metastasis [17].
CZ but not C3 bone tumor cells show properties of
invasion
An important difference between CZ and C3 osteosarcoma cell
lines was seen using a ‘Matrigel’ invasion assay in Boyden
chambers with coated membranes [22]. CZ osteosarcoma cells
readily invaded across the extracellular matrix barrier in response
to C3 bone tumor cell conditioned medium (Figure 3A). Migration
of these cells through the barrier was stimulated 6–8 fold over a
4 hour period. Tumor cells from F1 mice behaved like those from
CZ. In contrast, C3 tumor lines showed almost no ability to
penetrate the coated membranes under the same conditions. The
Table 1. Host control of metastasis in CZ, C3 and [CZ x C3] F1
mice.
Mouse strain No. of animals Osteosarcoma Lung Mx (%)
CZ 38 33 30 (91)
C3 106 18 0
[CZ X C3] F1 16 12 11 (92)
doi:10.1371/journal.ppat.1000733.t001
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metastatic behavior in vivo. Tumor lines established directly from
metastatic lesions in lungs of CZ and F1 mice behaved similarly to
those from primary tumors with respect to their properties of
migration (Figure 2A and C) and invasion (Figure 3A).
Invasion is linked to elevated levels of the
metalloproteinase MMP-2 and of NFAT as an upstream
regulator
The abilities of CZ and F1 tumor cells to penetrate ‘Matrigel’
suggests the involvement of one or more matrix metalloproteinases
(MMPs). A zymograph assay was used to identify MMPs and
estimate their levels of secretion. Conditioned medium from each of
the tumor cell lines was concentrated as sources of enzyme(s).
Gelatin was used as a substrate in the ‘in gel’ assay for detection of
MMP-2 or MMP-9, two metalloproteinases linked to invasion and
metastasis by bone tumor cells [23]. Clearing of the gel wasseen at a
single position of ,70kD corresponding in molecular weight to
MMP-2 (Figure 3B, top). Clearing was strongest for the three CZ
tumors and somewhat weaker for the F1 tumors. Conditioned
media from the C3 cell lines produced little or no clearing of the gel.
Tumor cell extracts were tested to confirm the presence of MMP-
2 and to compare levels among the lines. Extracts were separated by
SDS gel electrophoresis and immunoblotted with anti-MMP-2
antibody. MMP-2 was detected in each of the cell lines but levels
were higher in CZ and F1 compared to C3 tumor cells (Figure 3B,
bottom). Levels of endogenous MMP-2 were estimated by
Figure2. Osteopontin is the majorchemoattractantinducing bone tumorcell migration. A) Bone tumor cells (3610
5) were used in a Boyden
chamber assay using conditioned medium from C3 bone tumor cells as chemoattractant. Vertical bars represent mean number of cells migrating 6 S.D.
Solid bars show migration using conditioned medium. Empty bars show migration using serum-free medium as a control. B) Tumor cell migration was
assayed as in (A) using conditioned medium (CM) that was untreated (empty bars), pre-treated with anti-VEGF (hatched bars) or anti-OPN (solid bars).
Left panel – CZ I cells with osteosarcoma CM; Middle panel – CZ I cells with hemangioma CM; Right panel – hemangioma cells with hemangioma CM. C)
Tumor cell migration in response to recombinant OPN in serum-free medium (hatched bars) or serum-free medium alone (empty bars).
doi:10.1371/journal.ppat.1000733.g002
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averaged for the cell lines based on host of origin. The values
(arbitrary units) were 1.1460.22 for the three C3 lines, 3.7960.27
for the F1 lines and 5.1861.37 for the CZ lines. The tumor cells
from CZ thus expresses 4 to 5 fold higher levels of the protease than
those from C3. Comparison of the zymograph with the immunoblot
(Figure 3B) suggests that secreted levels of MMP-2 may be even
more disproportionate (CZ . C3). This would indicate that
differencesinthesecretorypathwayorextracellularactivationofthe
enzyme may also contribute to the ability to invade. Other MMPs
not directly tested for here may also be involved.
The finding of higher levels of MMP-2 secreted by CZ and F1
compared to C3 tumor cells raises the possibility of involvement of
the transcription factor NFAT [24]. NFAT is known to regulate
the expression of MMPs and to be involved in tumor cell invasion
[25,26]. To test this possibility, tumor cell extracts were separated
and blotted with antibody to NFATc1. This antibody detects three
alternatively spliced species among which there are no well
established functional differences [27,28]. The levels of all three
were elevated in tumor cells from CZ and F1 compared to C3
(Figure 4A). Relative levels of NFAT based on scanning across all
isoforms were as follows (arbitrary units): for the three C3 lines
384.3668.4, for F1 676.7658.5 and for CZ 1038.76157.3. To
measure levels of activated NFAT, tumor cells were transfected
with a luciferase reporter responsive to NFAT [29]. This reporter
carries elements from the IL-2 promoter and is known to be
responsive to NFAT [30]. CZ and F1 cells showed 3–4 fold
activation of the reporter compared to C3 cells (Figure 4B). These
results demonstrate higher levels of expression and activation
NFATc1 in the metastatic compared to the non-metastatic
osteosarcoma cell lines.
To test for the functional importance of MMP-2 and NFAT,
‘Matrigel’ invasion assays were carried out with the CZ II line in the
presence of TIMP-2 as a specific inhibitor of MMP-2 [31,32], or
following transfection with siRNAs to suppress NFAT expression
(Figure 4C). Addition of TIMP-2 resulted in a 3 to 4 fold inhibition
of invasion. Two siRNAs were used to directly inhibit expression of
NFAT. Both were effective in reducing NFAT levels with
concomitant effects on MMP-2. Importantly, both were effective
in inhibiting invasion. siRNA2 was particularly effective, reducing
MMP-2 levels 4 to 5 fold and blocking invasion 6 to 7 fold. Similar
results were obtained with all three CZ and all three F1 lines. Thus,
treatments targeting either the protease or its upstream regulator
result in inhibition of invasion. These results suggest that operation
of an NFAT R MMP-2 pathway at elevated levels contributes to
the metastatic behavior of osteosarcomas in CZ and F1 mice.
The CZ mouse model of osteosarcoma differs from
genetically engineered models
Several mouse models of osteosarcomahave been developedbased
on loss or alteration of p53 or pRb. These reflect the occurrence of
osteosarcoma in families with germline mutations in these tumor
suppressor genes and with their frequent somatic alterations in
sporadic cases of the disease. Mice with germline loss of p53 or ones
expressing certain gain-of-function mutants develop osteosarcoma
along with a variety of other tumors [33–35]. Loss of pRb by itself has
not beennoted togive riseto osteosarcoma, but when coupled to p53-
Figure 3. Metastatic tumor cells invade Matrigel via an MMP-2-mediated pathway. A) Migration assay was carried out as in Figure 2A
except the upper surface of the filter was coated with Matrigel. B) Upper – Zymography with gelatin as ‘in gel’ substrate and conditioned media from
each of the tumor lines. Lower – Immunoblot for MMP-2 in tumor cell lysates.
doi:10.1371/journal.ppat.1000733.g003
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ment of the disease [36,37]. Variable rates of metastasis are found in
these models. Interestingly, the frequency of p53 loss in osteosarcoma
patients with localized disease was found to be the same as in patients
with metastatic disease [38], suggesting that events beyond loss of p53
are important in metastasis. The events that give rise to metastasis
following disruption of the transcriptional regulatory functions of
these tumor suppressors are not known.
The predisposition to bone tumor metastasis in Py-infected CZ
mice is dominantly inherited and presumed to be independent of
p53 or pRb loss. Neither CZ nor C3 mice develop spontaneous
tumors at a rate that would suggest the absence or altered function
of p53 or pRb. Polyoma is unusual among the oncogenic DNA
tumor viruses in its failure to inhibit or degrade p53 in tumors [39].
The possibility of spontaneous loss of p53 in CZ osteosarcomas was
nevertheless investigated. Tumor cell lines from CZ, C3 and F1
mice were examined for p53 expression and for their response to
DNA damage (Figure 5). Cells were exposed to actinomycin D (10–
50 nM) for 24 hours. This led to phosphorylation on serine-18
(serine-15 in humans) and accumulation of p53 and to induction of
p21
Cip1/Waf1, as previously shown for cells in culture productively
infected by the virus [40]. Similar results were found for the other
lines (data not shown). pRb function is disrupted by binding to Py
large T antigen [41]. However, the ability of the virus to induce
tumors does not depend on this interaction [11], and metastatic
mammary tumors develop without large T in middle T transgenic
mice [16]. The large T-pRb interaction is expected to occur equally
in tumors of CZ, C3 and F1 mice. While disruption of pRb by large
T may be necessary for metastatic behavior, it is not sufficient. It
thus appears that the difference between CZ and C3 mice with
respect to bone tumor metastasis is based on host genetic factor(s)
unrelated to p53 loss or to the action of the virus on pRb.
As in the human disease, the downstream effectors of metastasis
in the engineered mouse models remain largely unknown.
Figure 4. Activation of NFAT and secretion of MMP-2 are critical for invasion by metastatic bone tumor cells. A) Immunoblot for NFAT
c1 in tumor cell lysates. B) Normalized luciferase activity of an NFAT reporter in tumor cells. C) Inhibition of invasion by CZ II tumor cells. Left: cells 6
TIMP-2. Middle: cells 6 NFAT siRNA. Right: immunoblots on cells 6 NFAT siRNA.
doi:10.1371/journal.ppat.1000733.g004
Polyoma Virus-Mouse Model of Bone Tumor Metastasis
PLoS Pathogens | www.plospathogens.org 6 January 2010 | Volume 6 | Issue 1 | e1000733Elevated expression of MMP-2 and NFAT are important factors
in the invasive behavior of CZ osteosarcoma cells in vitro.
Enhanced operation of a pathway linking these factors provides
a plausible mechanism contributing to the metastatic behavior of
osteosarcomas in CZ mice. The genetic determinant(s) of
metastasis in this system nevertheless remain unknown. Factors
that impinge on calcineurin activation of NFAT [29], on secretion
or activation of MMPs, expression of specific integrins involved in
tumor cell invasion [42], and microenvironmental influences in
the lung are among many additional factors that may be involved.
Mapping and identifying genetic determinants in this system will
be necessary to confirm the importance of the NFATRMMP-2
pathway and to fully establish the molecular basis of metastasis.
Materials and Methods
Induction of tumors in mice
Czech II/E mice (Jackson Laboratory, Bar Harbor, ME) and
C3H/BiDa mice (National Cancer Institute, Frederick, MD) were
maintained in our SPF barrier animal facility. No spontaneous
tumors were noted. Newborn mice wereinoculated i.p. with ,50 ml
of a crude virus suspension (RA strain, 225610
6 PFU), transferred
to a separate facility and monitored for tumor development as
described [14]. The methods for mice use and care were approved
by the Harvard Medical Area Standing Committee on Animals
(‘‘HMA IACUC’’), and are in accordance with PHS policy on Care
and Use of Laboratory Animals under the guidance of the Office of
Laboratory Animal Welfare (OLAW) within the NIH. Histology
was carried out through the Rodent Histopathology Core of the
Dana Farber-Harvard Cancer Center. Screening for lung metas-
tases was carried out by step-sectioning and microscopic examina-
tion. A total of five sections (5 m) taken 100 m apart were examined.
Osteosarcoma cell lines and conditioned media
Osteosarcomas were removed at necropsy, cut into small
fragments, washed and digested at 37u C overnight in medium
containing 200 U/ml Collagenase, Type 1 (Worthington). Cells were
spun out, resuspended and plated in DMEM containing 10% FBS.
Cells were expanded initially to five 10 cm dishes and frozen. All
experiments were carried out within 2–5 further passages. CZ-I and
CZ-II are from osteosarcomas in two individual CZ mice. CZ-Mxis a
lung metastasis from the same mouse as CZ-I. C3-I, C3-II and C3-III
are non-metastatic osteosarcma lines from three individual C3 mice.
F1-I and F1-II are from two F1 mice. F1-Mx is a lung metastasis from
the same mouse as F1-I. Conditioned medium was prepared from
confluent cultures of cells grown in DMEM with 10% FBS. Cultures
were washed and incubated at 37uC overnight in serum-free DMEM.
Media were concentrated ten fold using centrifugal filter devices
(Millipore Corporation). Concentrates were filter sterilized and stored
at 280uC. Levels of OPN and VEGF in conditioned media were
determined by double sandwich ELISA.
Assays for migration and invasion
Tumor cell migration and invasion were assayed using Boyden
chambers [22] with polycarbonate membranes (8 mm pore size;
6.5 mm diameter from Corning Inc., Corning, NY). Tumor cells
(3610
5/well in DMEM with 0.1% BSA) were placed in the upper
compartment and either conditioned medium or recombinant
osteopontin (4 mg/well; R&D Systems, Inc., Minneapolis, MN) in
the lower compartment. Incubation was at 37uC for 1 h. Where
indicated, conditioned medium was neutralized with anti-OPN or
anti-VEGF antibody (5 mg/well; R&D Systems, Inc). After
removal of cells from the upper side of the filter, cells on the
bottom side were stained by crystal violet and counted over 7
randomly chosen fields. Invasion assays were performed in the
same manner except that the polycarbonate filters were coated
with ECM gel (20 mg/well; Sigma). Tumor cells (5610
5) were
added to the upper chamber and incubated for 4 h at 37uC.
Gelatin zymography
Procedures were essentially as described [43]. Acetone precipi-
tates of concentrated conditioned media were resuspended and
separated on 10% polyacrylamide gel containing 1 mg/mL gelatin.
Immunoblotting
Cell extracts were separated by SDS-PAGE, transferred and
blotted with antibody against NFAT c1 (Santa Cruz Biotech, Santa
Cruz, CA), MMP-2 (Santa Cruz Biotech), phospho-p53 (ser-15) (Cell
Signaling, Beverly, MA), or p21 (C-19) (Santa Cruz Biotech).
Membranes were washed and incubated with Alexa fluor 680 anti-
mouse and 800 anti-rabbit IgG antibodies (Invitrogen, Carlsbad,
CA). Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, NE) was used to reveal band intensities and integrated
intensity values were obtained using LI-COR Odyssey software (Li-
COR Biosciences).
Luciferase assay
Cells were cotransfected with pTL-Renilla vector and pGL3
basic or pGL3 containing IL2 promoter by using Lipofectamin
2000 (Invitrogen) according to the manufacturer’s protocol. At
24 hr, cells were harvested, washed and lysed with 100 ml of Passive
lysis buffer (Promega, Madison, WI) at 4uC for 15 min. Twenty
microliters of the cell lysate and a Dual assay kit (Promega) were
used to measure fluorescence intensities. Firefly luciferase activities
were normalized to those of renilla luciferase.
siRNA transfection and TIMP-2 treatment
Cells were transfected with NFATc1 siRNA
(NFATC1MSS275981 and NFATC1MSS275982; Invitrogen) or
Stealth RNAi Negative Control Duplex (Invitrogen) using
Oligofectamin and Opti-MEM medium (Invitrogen). Levels of
NFAT at 24 hr post- transfection, were determined by
immunoblotting. TIMP-2 (400 ng/ml, Sigma) was used to pretreat
CZ and F1 bone tumor cells for 30 min and was added to the
upper and lower chambers during the assay.
Accession numbers (UniProtKB/Swiss-Prot)
72 kDa type IV collagenase : P33434 (MMP2_MOUSE)
Nuclear factor of activated T-cells, cytoplasmic 1 : O88942
(NFATc1_MOUSE)
Osteopontin : P10923 (Osteopontin_MOUSE)
Cellular tumor antigen p53 : P02340 (P53_MOUSE)
Figure 5. Induction of p53 and p21
Cip1/Waf1 in a DNA damage
response in metastatic and non-metastatic bone tumor cell
lines. Cell extracts were separated by SDS-PAGE and immunoblotted as
indicated. ActD – actinomycin D.
doi:10.1371/journal.ppat.1000733.g005
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